

To find the category (Medicare Stars, Federal Employee Program®, etc.) this measure applies to, see our [chart of HEDIS® measures](#).

Medication Management for People with Asthma (MMA)

Let's work together to improve health outcomes. The Healthcare Effectiveness Data and Information Set (HEDIS®) helps us measure many aspects of performance. This tip sheet details key points of the featured HEDIS measure.

What is the measure?

The measure records the percentage of members age 5-64 during the measurement year who were identified from claims as having persistent asthma and who remained on appropriate medications during the treatment period. There are two rates that are reported:

1. The percentage of members who remained on an asthma control medication for at least 50% of the treatment period.
2. The percentage of members who remained on an asthma control medication for at least 75% of the treatment period.

How to Improve Your Quality Score

- Report the appropriate diagnosis codes for the member's condition. Include the appropriate codes for the diagnosed conditions that may exclude the member from this measure.
- Ask if your patient has a barrier to filling the prescription. Many drug manufacturers have coupons available on their websites.
- Schedule follow-up appointments and ensure the patient receives prescriptions during the patient checkout process.

Exclusions

COPD	ICD-10: J44.0, J44.1, J44.9
Cystic fibrosis	ICD-10: E84.0, E84.11, E84.19, E84.8, E84.9
Acute respiratory failure	ICD-10: J96.0 - J96.02, J96.20-J96.22
Emphysema value set and other emphysema value set	ICD-10: J43.0-J43.2, J43.8, J43.9, J98.2-J98.3
Obstructive chronic bronchitis	ICD-10: 491.20-491.22
Chronic respiratory conditions due to fumes/vapors	ICD-10: J68.4
Members in hospice	CPT: 99377, 99378 HCPCS: G0182

(continued next page)

All summaries of the measures contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications f(continued next page) or Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Please see the final page of this document for the full copyright citation.

HEDIS Measure: Medication Management for People with Asthma (MMA) (continued)

Asthma Control Medications	
To be compliant, the member must be taking one of these asthma control medications:	
Antiasthma combinations	<ul style="list-style-type: none"> • Dyphylline-guaifenesin
Antibody inhibitors	<ul style="list-style-type: none"> • Omalizumab
Anti-interleukin-5	<ul style="list-style-type: none"> • Benralizumab • Mepolizumab • Reslizumab
Inhaled steroid combinations	<ul style="list-style-type: none"> • Budesonide-formoterol • Fluticasone-salmeterol • Fluticasone-vilanterol • Formoterol-mometasone
Inhaled corticosteroids	<ul style="list-style-type: none"> • Beclomethasone • Budesonide • Ciclesonide • Flunisolide • Fluticasone • Mometasone
Leukotriene modifiers	<ul style="list-style-type: none"> • Montelukast • Zafirlukast • Zileuton
Methylxanthines	<ul style="list-style-type: none"> • Theophylline

Content reproduced with permission from HEDIS® 2020, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of this publication, including the full measures and specifications, visit ncqa.org/publications.